IM JAHR 2012 BEWILLIGTES PROJEKT
Peptidic Targeted Transport System
Redaktion
Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.
Kooperation
Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen: Pharmaceutical Technology, Basel; LASCCO SA, Geneva
Projektdaten
Projekt-Nr.: GRS-048/11
Förderbeitrag: CHF 336'250
davon Löhne: CHF 288'250
Bewilligung: 26.01.2012
Dauer: 08.2012 - 06.2014
Projektleitung
Prof. Dr. Wolfgang Meier, Universität Basel, Physikalische Chemie, Klingelbergstrasse 80, 4056 Basel (Schweiz), wolfgang.meier@unibas.ch
Abstract
Gene therapy enables the relief and healing of diverse diseases on a genetic level. However it is reliant on a nano carrier system which allows the transportation to the addressed location and protects against early degeneration. In this context a new drug/ gene delivery system was developed while the carrier system is solely based on amino acids, which are similarly produced naturally in the body. Therefore body intrinsic degradation pathways allow the clearing after application. The system is convincing in terms of high drug/gene loading and functionality, but notable through the “natural” character, avoiding accumulation in the human body and thus eliminating harming side effects.The goal of the project is to develop a prototype as a universal platform in gene therapy. We will modify and optimize the carrier system to combat amyotrophic lateral sclerosis, a neurodegenerative disease in collaboration with Lascco SA. This project is the proof-of-principle and illustrates the potential of the delivery system, but similar may be the base for a start-up company.
Was ist das Besondere an diesem Projekt?
Drug delivery systems on purely peptidic base are yet not established. However our system has the potential to work as a prototype for future developments and progress in gene therapy.Stand/Resultate
Recent investigation clarified the details in the self-assembly of our purely peptidic system into a multi compartment micelles structure. Latter is especially beneficial in terms of encapsulating hydrophilic or hydrophobic drugs. In addition, preliminary experiments showed that our system is capable to embed even more demanding payload such as plasmid DNA without being cytotoxic.In collaboration with the Pharmaceutical Technology department of the University of Basel, LASCCO AG and the support of Gerbert Rüf Stiftung we are enabled to further optimize and test our system to put a new gene therapy tool in place to efficiently combat amyotrophic lateral sclerosis.
Publikationen
de Bruyn Ouboter, D., et al., Hierarchical Organization of Purely Peptidic Amphiphiles into Peptide Beads. The Journal of Physical Chemistry C, 2011. 115(30): p. 14583-14590;Schuster, T.B., et al., Reversible peptide particle formation using a mini amino acid sequence. Soft Matter, 2010. 6(21): p. 5596-5604.
Links
http://www.chemie.unibas.ch/~meier/index.htmlhttp://www.lascco.com
Am Projekt beteiligte Personen
Prof. Wolfgang Meier, Universität Basel, Projektleiter wolfgang.meier@unibas.chProf. J. Huwyler, Pharmaceutical Technology, University Basel Joerg.Huwyler@unibas.ch
Dirk de Bruyn Ouboter, Ph.D., Project advisor dirk.debruyn@unibas.ch
Thomas Schuster, Ph.D., Project advisor thomas.schuster@epfl.ch
Samareh Azeredo da Silveira Lajaunias, PhD, LASCCO SA, Geneva samareh.lajaunias@lascco.com